Atropos Health Launches Advanced Review Process for High-Quality Evidence at Scale
Atropos Health Introduces Robust Evidence Review Framework to Elevate Clinical Decision-Making In a significant step toward improving the reliability and scalability of real-world evidence (RWE), Atropos Health has announced the implementation of a comprehensive, multi-layered evidence review process. This initiative…
AACR 2026: STC-1010 Shows Safety & Early Immune Response in MSS Colorectal Cancer
AACR 2026: STC-1010 Shows Safety & Early Immune Activity in MSS CRC Brenus Pharma, a clinical-stage biotechnology company based in Lyon, France, has announced the presentation of new first-in-human data for its lead immunotherapy candidate, STC-1010, at the AACR Annual…
Imperative Care Launches ADAPT 2.0 Study to Streamline Acute Ischemic Stroke Treatment
Imperative Care Launches ADAPT 2.0 Study to Advance Stroke Treatment with Streamlined Aspiration Technique Imperative Care, a medical technology company dedicated to improving outcomes for patients with vascular diseases, has announced the enrollment of the first patients in its ADAPT…
Cryo-Cell Reports Q1 2026 Financial Results
Cryo-Cell International, Inc. Reports Fiscal First Quarter 2026 Financial Results Cryo-Cell International a pioneer in the cord blood banking industry, has announced its financial results for the first quarter of fiscal year 2026, which ended on February 28, 2026. As…
Prime Healthcare Wins Unanimous Approval for Illinois Expansion with Olympia Fields
Approval Clears Path for Acquisition of Franciscan Health Olympia Fields and Expansion of Community-Focused Care in Chicagoland Prime Healthcare has received unanimous approval from the Illinois Health Facilities and Services Review Board to move forward with its acquisition of Franciscan…
Douglas Emmett Forms Joint Venture to Acquire Premier Beverly Hills Medical Office Portfolio
Douglas Emmett JV Acquires Beverly Hills Medical Office Portfolio Douglas Emmett, a prominent real estate investment trust (REIT) specializing in high-quality office and multifamily properties in key coastal markets, has announced a significant strategic acquisition that further strengthens its dominance…
HeartBeam Announces Pricing of $10 Million Public Offering of Common Stock
HeartBeam Prices $10 Million Public Offering of Common Stock HeartBeam, Inc., a medical technology company dedicated to advancing cardiac care through innovative diagnostic solutions, has announced the pricing of its underwritten public offering of common stock, marking a significant step…
Prothena Announces Changes to Its Leadership Team
Prothena strengthens executive leadership with key appointments and strategic role transitions to support future growth Prothena Corporation plc, a late-stage clinical biotechnology company focused on addressing diseases driven by protein dysregulation, has announced a series of leadership team updates aimed…
NeuroPace to Present at Needham’s 25th Annual Virtual Healthcare Conference
NeuroPace to Present at 25th Annual Needham Virtual Healthcare Conference NeuroPace, Inc., a recognized innovator in the medical device industry, has announced its participation in the upcoming 25th Annual Needham Virtual Healthcare Conference. The company, which is dedicated to improving…
Johnson & Johnson Presents TECNIS PureSee IOL Data at ASCRS 2026 Showing Strong Vision Performance
Johnson & Johnson Showcases Strong Clinical Evidence for TECNIS PureSee™ IOL at ASCRS 2026 At the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting held in Washington, D.C., Johnson & Johnson unveiled compelling new clinical data supporting…
Centauri Launches First Wave of Patient-Centric Apps at CMS Health Tech Ecosystem: Live!
Centauri Showcases Patient-Centric Innovation at CMS Health Tech Ecosystem: Live! First Wave Launch At a landmark gathering focused on the future of digital healthcare, Centauri Health Solutions played a central role in demonstrating how real-time, patient-centered data exchange can transform…
Verastem Oncology Shares Two-Year Follow-Up Data for AVMAPKI+ FAKZYNJA in Recurrent LGSOC at SGO 2026
Verastem Oncology Presents Two-Year Follow-Up Data Highlighting Durable Benefits of AVMAPKI and FAKZYNJA Combination in Recurrent LGSOC Verastem Oncology has announced updated findings from the Phase 2 RAMP 201 clinical trial, showcasing two-year median follow-up data for its combination therapy…